The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action
To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Lung Tumors and the Investigation of Its Mechanism of Action.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Hung-Te Hsu, MD
- Phone Number: 7035 07-3121101
- Email: hdhsu1228@hotmail.com
Study Locations
-
-
-
Kaohsiung, Taiwan
- Recruiting
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Contact:
- Hung-Te Hsu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- eighteen to eighty-year-old
- ASA class I-III patients
- Received elective thoracic surgery for primary lung tumors under general anesthesia
Exclusion Criteria:
- mental disorder
- poor liver function
- pregnant or lactating women
- morbidly obese
- allergy to any of the drugs used in this study
- recurrent tumor or repeat surgery
- biopsy cases
- incomplete outcome-data
- palliative treatment after surgery
- simultaneous treatment of other malignancies
- emergency surgery
- presence of other malignant tumors
- combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine
- diagnosed as benign lung tumor, or other metastatic lung tumor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sevoflurane
The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
|
The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3
MAC)
Other Names:
|
|
Experimental: Propofol
The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
|
The propofol group was both induced and maintained at an effect-site concentration (Ce) of 2.0-4.0 mcg/mL by a target-controlled infusion (TCI) system.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: From the date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
6-month overall survival, 1-year overall survival, and 3-year overall survival
|
From the date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
|
|
The presence of disease progression
Time Frame: From the date of surgery until the date of first documented progression (recurrence or metastasis),assessed up to 36 months
|
From the date of surgery until the date of first documented progression (recurrence or metastasis) or date of death from any cause, assessed up to 36 months
|
From the date of surgery until the date of first documented progression (recurrence or metastasis),assessed up to 36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative complications
Time Frame: The period from the day of surgery to postoperative 30 days
|
Clavien-Dindo classification, and other postoperative complications
|
The period from the day of surgery to postoperative 30 days
|
|
Karnofsky performance status score
Time Frame: Karnofsky performance score(from 0 (dead) to 100(normal no complication)) before surgery (baseline data) , postoperation 7 days, postoperation 3 months, postoperation 6 months, postoperation 12 months
|
to access patients' functional impairment
|
Karnofsky performance score(from 0 (dead) to 100(normal no complication)) before surgery (baseline data) , postoperation 7 days, postoperation 3 months, postoperation 6 months, postoperation 12 months
|
|
Length of hospital stays
Time Frame: from the day of surgery to dischage, assessed up to 30 days
|
the length of stays in general ward and ICU
|
from the day of surgery to dischage, assessed up to 30 days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
time of operation and anesthesia
Time Frame: time of the total procedure
|
record the time the opeartion and anesthesia
|
time of the total procedure
|
|
blood loss
Time Frame: during the operation of VATS
|
record the blood loss (ml)
|
during the operation of VATS
|
|
volume of blood transfusion
Time Frame: during the operation of VATS
|
volume of blood transfusion (ml)
|
during the operation of VATS
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KMUHIRB-F(I)-20210218.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.